Signal Genetics, Inc. (NASDAQ: SGNL) Begins Patient Study for its MyPRS(R) Assay
NEW YORK, NY / ACCESSWIRE / January 12, 2016 / Signal Genetics, Inc. (SGNL) has entered into an agreement with the University of Texas MD Anderson Cancer Center to further validate the clinical utility of its MyPRS(R) test which identifies patients at risk of rapid progression from the precursor conditions of smoldering multiple myeloma and MGUS (collectively, asymptomatic monoclonal gammopathies, or AMG) to symptomatic multiple myeloma. The parties have designed a prospective study enrolling approximately 200 patients.
Signal Genetics, Inc. is a commercial stage, molecular diagnostic company providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer.
To find out more about the agreement with the University of Texas MD Anderson Cancer Center and the company get our brief report at the link below. There is no cost or obligation to review this report.
http://bit.ly/1RI0oOI Copy and paste to browser may be required.
About Broad Street Alerts
We make the connection between sophisticated investors and high quality micro and small cap companies. An issuer of reports that provide a straightforward assessment of the profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.
Safe Harbor Statement
This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party analyst. However, we are only human and may make mistakes. If you notice any errors or omissions, please notify us. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and coinciding reports. For more information and services provided beyond this press release please use contact information provided below.
Contact: editor@Broadstreetalerts.com
SOURCE: Broad Street Alerts
